The nation of Zimbabwe has turned down a significant US healthcare agreement valued at 367 million US dollars (£272m) over five years over Washington's insistence on confidential biological samples.
This rejection was revealed after a government memo from December was leaked, which showed Head of State Emmerson Mnangagwa deemed the deal was "unbalanced".
A government spokesman later clarified that the United States was demanding access to biological samples for scientific study and commercial purposes but was unwilling to share the benefits from future vaccines.
"We are forced to start the difficult and regrettable process of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for further negotiations to reach a deal suitable to both sides so the nation's critical HIV treatment initiative can proceed.
Wider Implications
This rejection follows a comparable case in neighbouring Kenya, where a court suspended a similar health funding agreement after concerns were filed about the security of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump argued its expenditure was "wasteful" and his government was pursuing direct bilateral deals to boost transparency and responsibility.
As per reports, 16 African countries have to date signed similar health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership would have delivered immense benefits for Zimbabwean communities, especially the 1.2 million presently receiving HIV treatment via American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, with no equivalent guarantee of access to any medical innovations – such as new medicines or tests – that could result from that shared data," he stated.
"In essence, our nation would provide the raw materials for medical research without any assurance that the resulting innovations would be accessible to our people if a new disease outbreak arise."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining structures already set up through the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to manage potential global health emergencies.
"This system is designed to guarantee that when a nation provides its information, the benefits – such as medicines and cures – are shared equitably, not commercialised solely by those with the capability to develop them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome ongoing discussions with our American counterparts on how future co-operation might be designed in a manner that honours the independence and interests of each country."
Health Experts Reaction
A leading public health body expressed it recognised the official position, but recommended that negotiations need to persist given that much of the country's Aids initiatives were funded by foreign aid.
"In cases where specific concerns exist, including those relating to data governance or agreement terms, these can often be addressed through technical clarification and negotiated safeguards," the group added.
This impasse underscores the complex tensions between receiving vital foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.